Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 19;14(4):1059.
doi: 10.3390/cancers14041059.

The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review

Affiliations
Review

The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review

Kyra Bokkers et al. Cancers (Basel). .

Abstract

Background: Non-genetic healthcare professionals can provide pre-test counseling and order germline genetic tests themselves, which is called mainstream genetic testing. In this systematic review, we determined whether mainstream genetic testing was feasible in daily practice while maintaining quality of genetic care.

Methods: PubMed, Embase, CINAHL, and PsychINFO were searched for articles describing mainstream genetic testing initiatives in cancer care.

Results: Seventeen articles, reporting on 15 studies, met the inclusion criteria. Non-genetic healthcare professionals concluded that mainstream genetic testing was possible within the timeframe of a routine consultation. In 14 studies, non-genetic healthcare professionals completed some form of training about genetics. When referral was coordinated by a genetics team, the majority of patients carrying a pathogenic variant were seen for post-test counseling by genetic healthcare professionals. The number of days between cancer diagnosis and test result disclosure was always lower in the mainstream genetic testing pathway than in the standard genetic testing pathway (e.g., pre-test counseling at genetics department).

Conclusions: Mainstream genetic testing seems feasible in daily practice with no insurmountable barriers. A structured pathway with a training procedure is desirable, as well as a close collaboration between genetics and other clinical departments.

Keywords: cancer; feasibility; genetic counseling; mainstream genetic testing; quality of care; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prisma flow chart.
Figure 2
Figure 2
Turnaround times from diagnosis to disclosure of the test result in the patient. Note: if multiple turnaround times were mentioned in one study, these turnaround times are all shown separately. In the articles, turnaround times were reported as calendar days, working days or weeks and these are all shown here as calendar days. Turnaround times of the standard genetic testing pathway are shown between brackets if they were mentioned in the articles.

References

    1. Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Goggins M., Hutton M.L., et al. NCCN Clinical Practice Guideline in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021. J. Natl. Compr. Cancer Netw. 2021;19:77–102. doi: 10.6004/jnccn.2021.0001. - DOI - PubMed
    1. Swisher E.M. Usefulness of Multigene Testing: Catching the Train That’s Left the Station. JAMA Oncol. 2015;1:951–952. doi: 10.1001/jamaoncol.2015.2699. - DOI - PubMed
    1. Yadav S., Hu C., Hart S.N., Boddicker N., Polley E.C., Na J., Gnanaolivu R., Lee K.Y., Lindstrom T., Armasu S., et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. J. Clin. Oncol. 2020;38:1409–1418. doi: 10.1200/JCO.19.02190. - DOI - PMC - PubMed
    1. De Bono J., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K.N., Sartor O., Agarwal N., Olmos D., et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020;382:2091–2102. doi: 10.1056/NEJMoa1911440. - DOI - PubMed
    1. Tew W.P., Lacchetti C., Ellis A., Maxian K., Banerjee S., Bookman M., Jones M.B., Lee J.M., Lheureux S., Liu J.F., et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J. Clin. Oncol. 2020;38:3468–3493. doi: 10.1200/JCO.20.01924. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources